English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We demonstrated that Lp(a) levels in patients with arteriosclerosis obliterans (21.4 +/- 2.5 mg/dl) and in patients with ischemic heart disease (17.2 +/- 0.8 mg/dl) are higher than those in controls (15.4 +/- 0.7 mg/dl) or healthy controls (11.3 +/- 1.1 mg/dl). Lp(a) levels in patients with these vascular diseases were especially higher when there were known atherosclerotic risk factors such as diabetes mellitus, hypercholesterolemia or hypertension, although Lp(a) levels in patients with these risk-positive group was not different from that of control. These results suggest that Lp(a) contributes to the development of atherosclerotic vascular diseases especially when known atherosclerotic risk factors are not present. We also investigated the case of thromboangiitis obliterans, which is believed to develop from nonatherosclerotic mechanisms, and found that Lp(a) levels were higher (26.5 +/- 9.6 mg/dl) in such patients.

Contribution of Lp (a) to the Occurrence of Vascular Diseases : Correlation of Several Risk Factors Including Diabetes Mellitus